SB
SCLN

Suntrust Banks’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Suntrust Banks’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-11,938
Closed -$155K – 1610
2016
Q2 		$155K Buy
11,938
+432
+4% +$5.66K ﹤0.01% 1426
2016
Q1 		$126K Hold
11,506
– – ﹤0.01% 1409
2015
Q4 		$105K Buy
+11,506
New +$96.3K ﹤0.01% 1403

Other funds holding SCLN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Suntrust Banks's SCLN Position: Q3 2016 in Review

Suntrust Banks sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2016, closing a stake of 11,938 shares — an estimated $155K sold.

Suntrust Banks first reported a position in SCLN in Q4 2015 and held it in 3 quarters. The position peaked at $155K in Q2 2016. 151 funds tracked by Wall St. Rank hold SCLN as of Q3 2016.

  • Suntrust Banks reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2016 after selling out during the quarter.
  • Suntrust Banks sold 11,938 Sciclone Pharmaceuticals Inc shares in Q3 2016, an estimated $155K.
  • Suntrust Banks first reported a position in Sciclone Pharmaceuticals Inc in Q4 2015 and held it in 3 quarters.
  • Suntrust Banks's Sciclone Pharmaceuticals Inc position peaked at $155K in Q2 2016.
  • 151 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2016.

Based on Suntrust Banks's 13F filing for Q3 2016, filed 9 Nov 2016.